How does the micro-cap biotech now finance a 700-patient phase 3 study?

The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.

The company’s SGR-3515 features among the latest industry projects newly into first-in-human trials.

A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?

NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.

Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.

$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.